摘要
目的研究瑞舒伐他汀联合门冬胰岛素治疗糖尿病肾病(DN)的效果。方法对该院2019年5月—2020年5月80例DN患者进行研究,以随机数字表法将其分为各40例的对照组(门冬胰岛素单药治疗)及研究组(瑞舒伐他汀+门冬胰岛素治疗)。对比疗效。结果治疗后两组血糖指标、血脂指标、肾功能指标均下降,相比组内治疗前指标,差异有统计学意义(P<0.05)。治疗后研究组血糖指标、血脂、肾功能指标比对照组低,差异有统计学意义(P<0.05)。结论门冬胰岛素治疗DN基础上联合瑞舒伐他汀对血糖、血脂的控制效果更好,能阻止、延缓DN的发展,该治疗方案值得在临床中应用。
Objective To study the effect of rosuvastatin combined with insulin aspart in the treatment of diabetic nephropathy(DN).Methods A study of 80 DN patients in the hospital from May 2019 to May 2020 and divided them into a control group(insulin aspart monotherapy)and a study group(rosuvastatin+insulin aspart treatment)of 40 cases using a random number table.Contrast efficacy.Results After treatment,the two groups of blood glucose indexes,blood lipid indexes,and renal function indexes all decreased,and the difference was statistically significant compared with the indexes in the group before treatment,the difference was statistically significant(P<0.05).After treatment,the blood glucose,blood lipids,and renal function indexes of the study group were lower than those of the control group,and the difference was statistically significant(P<0.05).Conclusion Based on the treatment of DN with insulin aspart,the combination of rosuvastatin has a better control effect on blood glucose and blood lipids,and can prevent and delay the development of DN.This treatment plan is worthy of clinical application.
作者
李志龙
LI Zhilong(Department of Nephrology,Huidong County People's Hospital,Huizhou,Guangdong Province,516300 China)
出处
《糖尿病新世界》
2021年第6期169-171,共3页
Diabetes New World Magazine
作者简介
李志龙(1987-),男,本科,主治医师,研究方向为内科学、肾内科。
